Equities
  • Price (USD)67.83
  • Today's Change-1.69 / -2.43%
  • Shares traded15.06m
  • 1 Year change410.00%
  • Beta--
Data delayed at least 15 minutes, as of Aug 13 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

  • Revenue in USD (TTM)105.84m
  • Net income in USD-487.25m
  • Incorporated2016
  • Employees830.00
  • Location
    Moderna Inc200 Technology SqCambridge 02139-3578United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Catalent Inc2.87bn109.80m14.29bn12.30k118.206.2240.624.980.74280.742819.2918.040.49646.824.36233,528.502.383.692.724.2231.5131.814.796.471.552.050.53370.002.226.628.8748.7012.25--
Horizon Therapeutics PLC1.52bn517.40m15.15bn1.23k29.296.0619.539.982.452.457.6511.830.36816.723.231,264,749.0012.55-0.344415.62-0.410473.3964.9534.09-1.191.452.420.3326--7.6634.35856.24--38.53--
Cardinal Health Inc153.59bn-4.16bn15.71bn49.50k--13.06--0.1023-14.04-14.04519.754.123.7511.5318.183,102,748.00-10.142.60-24.916.024.535.16-2.710.72680.52867.550.857659.416.389.83300.443.225.679.50
Alnylam Pharmaceuticals, Inc.345.18m-846.17m15.84bn1.32k--11.29--45.90-7.57-7.573.0812.100.11340.85796.91260,907.00-27.79-35.69-31.47-39.3685.34---245.14-600.535.42-632.030.00--193.3634.16-16.24--32.78--
Incyte Corporation2.39bn-191.07m20.33bn1.46k--8.65--8.52-0.9112-0.911210.9310.750.77528.876.611,639,780.00-6.203.65-7.304.3795.7596.02-8.004.763.70--0.02160.0014.7133.37308.16--22.87--
AmerisourceBergen Corp.186.29bn1.57bn21.14bn22.00k13.685.4810.590.11357.577.57893.4318.914.7015.7113.868,467,589.003.982.1116.088.732.622.780.84670.44350.589912.830.510643.626.948.48-21.7523.773.2411.22
BioMarin Pharmaceutical Inc.1.85bn122.26m21.19bn3.00k177.556.5491.1611.470.6580.65810.0717.870.3810.60824.87615,492.802.52-4.792.90-5.5678.2380.386.62-15.012.34-7.240.3096--14.2717.8669.11--6.90--
McKesson Corporation231.00bn922.00m24.82bn80.00k27.934.5512.120.10745.485.471,310.6533.623.8713.1912.472,887,525.001.912.835.758.005.175.530.49260.79930.57191.690.513118.067.815.231,809.43-12.59-1.4710.76
Seattle Genetics, Inc.1.02bn-255.68m26.71bn1.61k--14.71--26.30-1.50-1.505.9310.430.54421.234.30632,759.50-13.70-14.09-15.84-16.7690.1190.52-25.18-27.334.39--0.00--40.0226.1728.76--32.73--
Moderna Inc105.84m-487.25m27.21bn830.00--9.20--257.13-1.40-1.400.30277.490.0409--5.59127,519.30-18.84---20.10-------460.36------0.0226---55.42---27.91------
Iqvia Holdings Inc10.94bn132.00m31.15bn67.00k244.525.5722.252.850.66610.666155.9129.230.473--4.58163,268.700.70491.500.84911.8333.4433.191.492.88--1.720.67420.006.4915.22-14.73-11.7347.75--
Data as of Aug 13 2020. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

23.64%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202024.76m6.37%
The Vanguard Group, Inc.as of 31 Mar 202020.39m5.25%
BlackRock Fund Advisorsas of 31 Mar 202011.55m2.97%
Th�l�me Partners LLPas of 31 Mar 20208.93m2.30%
SSgA Funds Management, Inc.as of 31 Mar 20205.50m1.41%
Federated Global Investment Management Corp.as of 31 Mar 20204.67m1.20%
Invesco Advisers, Inc.as of 31 Mar 20204.40m1.13%
Morgan Stanley Investment Management, Inc.as of 31 Mar 20204.21m1.08%
Bellevue Asset Management AGas of 31 Mar 20203.95m1.02%
Baillie Gifford & Co.as of 31 Mar 20203.56m0.92%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.